Artivion Inc (AORT) - Total Assets
Based on the latest financial reports, Artivion Inc (AORT) holds total assets worth $883.16 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AORT debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Artivion Inc - Total Assets Trend (1991–2025)
This chart illustrates how Artivion Inc's total assets have evolved over time, based on quarterly financial data. See Artivion Inc book value and equity for net asset value and shareholders' equity analysis.
Artivion Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Artivion Inc's total assets of $883.16 Million consist of 34.3% current assets and 65.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.3% |
| Accounts Receivable | $103.68 Million | 11.7% |
| Inventory | $92.43 Million | 10.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $156.50 Million | 17.7% |
| Goodwill | $254.09 Million | 28.7% |
Asset Composition Trend (1991–2025)
This chart illustrates how Artivion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Artivion Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Artivion Inc's current assets represent 34.3% of total assets in 2025, a decrease from 79.8% in 1991.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 10.1% in 1991.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 2.0% in 1991.
- Asset Diversification: The largest asset category is goodwill at 28.7% of total assets.
Artivion Inc Competitors by Total Assets
Key competitors of Artivion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
APT Medical Inc
SHG:688617
|
China | CN¥3.43 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.02 Billion |
Artivion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 5.53 | 4.04 |
| Quick Ratio | 2.22 | 3.95 | 2.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $211.40 Million | $235.36 Million | $179.11 Million |
Artivion Inc - Advanced Valuation Insights
This section examines the relationship between Artivion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.74 |
| Latest Market Cap to Assets Ratio | 1.31 |
| Asset Growth Rate (YoY) | 12.1% |
| Total Assets | $884.80 Million |
| Market Capitalization | $1.16 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Artivion Inc's assets above their book value (1.31x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Artivion Inc's assets grew by 12.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Artivion Inc (1991–2025)
The table below shows the annual total assets of Artivion Inc from 1991 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $884.80 Million | +12.13% |
| 2024-12-31 | $789.10 Million | -0.42% |
| 2023-12-31 | $792.40 Million | +3.88% |
| 2022-12-31 | $762.80 Million | -3.81% |
| 2021-12-31 | $793.05 Million | +0.46% |
| 2020-12-31 | $789.40 Million | +30.34% |
| 2019-12-31 | $605.65 Million | +6.05% |
| 2018-12-31 | $571.09 Million | -3.48% |
| 2017-12-31 | $591.67 Million | +87.15% |
| 2016-12-31 | $316.14 Million | +74.49% |
| 2015-12-31 | $181.18 Million | +2.85% |
| 2014-12-31 | $176.16 Million | +0.84% |
| 2013-12-31 | $174.68 Million | +11.15% |
| 2012-12-31 | $157.16 Million | +6.28% |
| 2011-12-31 | $147.86 Million | +7.59% |
| 2010-12-31 | $137.44 Million | +2.67% |
| 2009-12-31 | $133.86 Million | +6.24% |
| 2008-12-31 | $126.00 Million | +35.94% |
| 2007-12-31 | $92.68 Million | +16.05% |
| 2006-12-31 | $79.86 Million | +3.98% |
| 2005-12-31 | $76.81 Million | +4.84% |
| 2004-12-31 | $73.26 Million | -2.35% |
| 2003-12-31 | $75.03 Million | -29.50% |
| 2002-12-31 | $106.41 Million | -17.71% |
| 2001-12-31 | $129.31 Million | +15.45% |
| 2000-12-31 | $112.01 Million | +19.13% |
| 1999-12-31 | $94.03 Million | -4.45% |
| 1998-12-31 | $98.40 Million | +83.24% |
| 1997-12-31 | $53.70 Million | +53.43% |
| 1996-12-31 | $35.00 Million | +48.31% |
| 1995-12-31 | $23.60 Million | +10.28% |
| 1994-12-31 | $21.40 Million | +6.47% |
| 1993-12-31 | $20.10 Million | +62.10% |
| 1992-12-31 | $12.40 Million | +13.76% |
| 1991-12-31 | $10.90 Million | -- |
About Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid… Read more